Online Only Articles

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;Institute of Hematology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland;Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland
Vol. 104 No. 7 (2019): July, 2019 https://doi.org/10.3324/haematol.2018.214759